Switzerland · Delayed Price · Currency is CHF Cosmo Pharmaceuticals Company Description
Cosmo Pharmaceuticals N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally.
The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, an injectable composition to allow endoscopists with excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Rifamycin, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers’ diarrhoea; and Clascoterone, which is in phase-3 clinical trial for the treatment of male pattern hair loss.
It is also developing novel UC treatment, which is in phase-2 clinical trial for the treatment of distal inflammatory bowel disease/distal ulcerative colitis/proctitis; BAD Treatment (CB-01-33), which is in phase-2 clinical trial for the treatment of colesevelam formulation/bile acid diarrhea; and CB-03-10, which is in phase-1 clinical trial for the treatment of oncology solid tumors, as well as provides Cosmo’s AI technology, a GI Genius intelligent endoscopy system.
The company was founded in 1997 and is headquartered in Dublin, Ireland.
| Country | Netherlands |
| Founded | 1997 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 332 |
| CEO | Giovanni Di Napoli |
Contact Details
Address: Riverside 2 Dublin, D02 KV60 Ireland | |
| Phone | 353 1 817 0370 |
| Website | cosmopharma.com |
Stock Details
| Ticker Symbol | COPN |
| Exchange | SIX Swiss Exchange |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | NL0011832936 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Giovanni Di Napoli | Chief Executive Officer and Director |
| Alessandro E. Della Cha LL.M | Non Executive Chairman |
| Mauro Severino Ajani | Founder and Non-Executive Director |
| Niall Donnelly | Executive Vice President of Corporate Governance, Chief Sustainability Officer and Executive Director |
| Svetlana Sigalova | Chief Financial Officer |
| Davide Malavasi | Qualified Person and Technical Director |
| Luigi Longo | Chief Scientific Officer |
| Federico Sommariva | Chief Legal Counsel |
| Ngo Dinh Nhan | President of Cosmo Intelligent Medical Devices |
| Andrea Cherubini | Chief AI Officer |